D-0661-2021 Class I Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

Recall Details

Product Type
Drugs
Report Date
July 14, 2021
Initiation Date
June 18, 2021
Termination Date
April 4, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10,425 vials

Product Description

Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PA 19454, Carton NDC# 0703-4714-01, Vial NDC# 0703-4714-71

Reason for Recall

Presence of Particulate Matter: Complaint received of a glass particle observed inside the vial. The vial was returned to Teva for further analysis where two other particulates were found and identified as one (1) grey silicone particle and one (1) translucent, colorless cotton fiber.

Distribution Pattern

Distributed Nationwide in the USA

Code Information

Lot # 31328962B, exp. date 04/2022